An interventional study of White Wine and Red Wine in Atherosclerosis Cardiovascular Disease, Obesity and Metabolic Syndrome, sponsored by University of Seville. Recruiting at 1 site in Spain. Open to participants aged 35 Years to 36 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-23.
Sponsored by University of Seville · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 390 studies in Obesity with a site in Spain — 95 open to participants now, 134 under way, 45 of them phase 3. Obesity · Spain.
Among the 390 studies in Obesity with a site in Spain, this one is the 331st largest by planned enrollment of the 332 interventional ones that give a count, is one of 52 that started in 2025, is one of 220 with no phase, reaches primary completion later than 28 of the 133 other live ones, and was the 337th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →95 of the 390 studies in Obesity with a site in Spain are open now. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in Spain, United States, Germany and 1 more country
Ages 45–65 · Women only
Boehringer Ingelheim · Sites in Spain, United States, Germany and 1 more country
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Argentina and 8 more countries
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Belgium and 7 more countries
Ages 6–11
AstraZeneca · Sites in Spain, United States, Argentina and 13 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 35 Years to 36 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
390 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 24 · Phase 3 81 · Phase 4 7
First in 2001; this study’s year is marked. 52 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 8 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 124 across the 332 interventional studies, 128 across the 57 observational. Of the 208 that completed or were terminated, 26 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
121 of 390 have an industry lead sponsor. The 10 most frequent:
University of Seville is the lead sponsor of 131 studies on the registry; 39 are open to participants now.
University of Seville has 3 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
33 of the studies in Obesity with a site in Spain that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07332273Phase 3Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludLevothyroxine as Adjuvant to a Hypocaloric Diet for the Treatment of Obesity. | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
Add all 33 to your calendar (.ics) → With an account.
Among the 390 studies in Obesity with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate how moderate wine consumption influences circulating extracellular vesicles (EVs) in healthy adults. EVs are small particles released by cells that carry proteins, lipids, and genetic material, and play important roles in communication between cells. Participants will consume a single serving of red or white wine, and blood samples will be collected before and after consumption to study changes in the composition and function of EVs. The study will also assess how these EVs affect vascular, immune, and brain-related cells. The results are expected to improve our understanding of how moderate wine intake contributes to cardiovascular and brain health.
Dietary interventions have been consistently proposed as a part of a comprehensive strategy to lower the incidence and severity of atherosclerosis and coronary vascular disease. According to the Dietary Guidelines for Americans 2015-2020, moderate red wine consumption-defined as up to two units of alcohol per day for men and up to one unit of alcohol per day for women-significantly reduces the risk of cardiovascular disease (CVD). Wine is a complex matrix consisting primarily of water (86%) and ethyl alcohol (12%), as well as other different molecules, such as polyphenols, organic acids, tannins, compound minerals, vitamins and biologically active compounds. While most of the nutritional studies have focused on elucidating the mechanisms by which biologically active compounds directly affect cardiovascular-related events, little or nothing is known about the regulatory effect of wine consumption on extracellular vesicles (EVs). EVs are small phospholipid particles that convey molecular bioactive cargoes and play essential roles in intercellular communication and, hence, a multifaceted role in health and disease. Recent advances in research on EVs have significantly enhanced their potential as therapeutic agents for neurological diseases. Owing to their therapeutic properties and ability to cross the blood-brain barrier (BBB), extracellular vesicles are recognized as promising drug delivery vehicles (e.g. polyphenols) for various neurological conditions. For the first time, the purpose of this project is to establish whether the moderate wine consumption may alter the structure, cargo, and functionality of postprandial EVs. In the precision nutrition era, we expect to offer a new insight on EVs and their relationship with wine through the following objectives: 1) To map changes in the lipidome, proteome, polyphenolic cargo, and functional properties of circulating EVs in healthy subjects both at fasting and at postprandial state upon a challenge of a one unit of red or white wine; 2) To analyse the effect of postprandial EVs on atherosclerotic-related events in endothelial and immune cells. 3) To analyse the effect of postprandial EVs on healthy ageing in blood-brain barrier and microglial cells. Collectively, this project will provide fundamental insight into EV biology and remarks the clinical and functional relevance and consequences of moderate wine consumption in health and disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will consume red wine (Cabernet Sauvignon) at a dose of 4 mL per kg body weight within 15 minutes. Blood samples will be collected at fasting (0 h), postprandial peak (1-2 h), and post-peak (6 h).
Dietary Supplement: Red Wine
Participants will consume white wine (Chardonnay) at a dose of 4 mL per kg body weight within 15 minutes. Blood samples will be collected at fasting (0 h), postprandial peak (1-2 h), and post-peak (6 h).
Dietary Supplement: White Wine
Participants will consume water (4 mL per kg body weight) within 15 minutes, serving as the control condition. Blood samples will be collected at fasting (0 h), postprandial peak (1-2 h), and post-peak (6 h).
Dietary Supplement: Water
Chardonnay, 4 mL/kg body weight
Cabernet Sauvignon, 4 mL/kg body weight
Still water, 4 mL/kg body weight
Concentration of circulating extracellular vesicles
Concentration of plasma-derived extracellular vesicles measured after acute intake of red wine, white wine, or water. Extracellular vesicles will be isolated by immunoaffinity methods and quantified using nanoparticle-based analysis. Results will be expressed as particles per milliliter (particles/mL).
Time frame: Baseline (0 hours), postprandial peak (2 hours after beverage intake), and post-peak (6 hours after beverage intake).
Mean size of circulating extracellular vesicles
Mean diameter of plasma-derived extracellular vesicles measured after acute intake of red wine, white wine, or water. Extracellular vesicle size will be assessed using dynamic light scattering. Results will be expressed in nanometers (nm).
Time frame: Baseline (0 hours), postprandial peak (2 hours after beverage intake), and post-peak (6 hours after beverage intake).
Postprandial changes in extracellular vesicle proteome
Postprandial changes in the protein composition of plasma-derived extracellular vesicles following acute intake of red wine, white wine, or water. EV-associated proteins will be analyzed using quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS). Results will be expressed as normalized protein abundance.
Time frame: Baseline (0 hours), postprandial peak (2 hours after beverage intake), and post-peak (6 hours after beverage intake).
Postprandial changes in extracellular vesicle lipidome
Postprandial changes in the lipid composition of plasma-derived extracellular vesicles following acute intake of red wine, white wine, or water. EV-associated lipid species will be analyzed using quantitative lipidomics by liquid chromatography-mass spectrometry (LC-MS). Results will be expressed as normalized lipid abundance.
Time frame: Baseline (0 hours), postprandial peak (2 hours after beverage intake), and post-peak (6 hours after beverage intake).
Change from baseline in plasma glucose concentration
Venous blood plasma glucose concentration measured using a validated clinical chemistry assay (enzymatic method). Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: mg/dL
Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake
Change from baseline in plasma insulin concentration
Venous blood plasma insulin concentration measured using a validated immunoassay. Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: µIU/mL
Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake
Change from baseline in plasma triglyceride concentration
Venous blood plasma triglyceride concentration measured using a validated clinical chemistry assay (enzymatic method). Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: mg/dL
Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake
Change from baseline in plasma total cholesterol concentration
Venous blood plasma total cholesterol concentration measured using a validated clinical chemistry assay (enzymatic method). Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: mg/dL
Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake
Change from baseline in plasma HDL cholesterol concentration
Venous blood plasma HDL cholesterol concentration measured using a validated clinical chemistry assay (enzymatic method). Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: mg/dL
Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake
Change from baseline in plasma LDL cholesterol concentration
Venous blood plasma LDL cholesterol concentration measured using a validated clinical chemistry assay (enzymatic method). Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: mg/dL
Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake
Change from baseline in plasma interleukin-6 (IL-6) concentration
Venous blood plasma IL-6 concentration measured using a validated immunoassay. Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: pg/mL
Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake
Change from baseline in plasma tumor necrosis factor alpha (TNF-α) concentration
Venous blood plasma TNF-α concentration measured using a validated immunoassay. Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: pg/mL
Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake
Change from baseline in plasma interleukin-1 beta (IL-1β) concentration
Venous blood plasma IL-1β concentration measured using a validated immunoassay. Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: pg/mL
Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake
Change from baseline in plasma monocyte chemoattractant protein-1 (MCP-1/CCL2) concentration
Venous blood plasma MCP-1/CCL2 concentration measured using a validated immunoassay. Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: pg/mL
Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake
Transendothelial electrical resistance (TEER) in an in vitro human blood-brain barrier model after exposure to postprandial extracellular vesicles
lood-brain barrier (BBB) integrity assessed by transendothelial electrical resistance (TEER) in a human in vitro BBB model after exposure to extracellular vesicles (EVs) isolated from plasma at baseline (0 hours) and postprandial peak (2 hours). Unit of Measure: Ω·cm²
Time frame: EVs isolated at baseline (0 hours) and 2 hours after beverage intake; TEER assessed within 72 hours after EV isolation
Claudin-5 (CLDN5) protein expression in an in vitro human blood-brain barrier model after exposure to postprandial extracellular vesicles
Tight junction protein expression assessed in the BBB model by Claudin-5 (CLDN5) protein abundance after exposure to EVs isolated at baseline (0 hours) and 2 hours post intake. Protein expression quantified using immunoblotting or immunofluorescence and reported relative to the control condition. Unit of Measure: Fold change (dimensionless)
Time frame: EVs isolated at baseline (0 hours) and 2 hours after beverage intake; protein expression assessed within 72 hours after EV isolation
Occludin (OCLN) protein expression in an in vitro human blood-brain barrier model after exposure to postprandial extracellular vesicles
Tight junction protein expression assessed in the BBB model by occludin (OCLN) protein abundance after exposure to EVs isolated at baseline (0 hours) and 2 hours post intake. Protein expression quantified using immunoblotting or immunofluorescence and reported relative to the control condition. Unit of Measure: Fold change (dimensionless)
Time frame: EVs isolated at baseline (0 hours) and 2 hours after beverage intake; protein expression assessed within 72 hours after EV isolation
Interleukin-6 (IL-6) concentration in microglial culture supernatant after exposure to postprandial extracellular vesicles
Microglial activation assessed by IL-6 concentration in culture supernatant after exposure to EVs isolated at baseline (0 hours) and 2 hours post intake. Cytokine concentration quantified using a validated immunoassay. Unit of Measure: pg/mL
Time frame: EVs isolated at baseline (0 hours) and 2 hours after beverage intake; cytokines assessed within 72 hours after EV isolation
Tumor necrosis factor alpha (TNF-α) concentration in microglial culture supernatant after exposure to postprandial extracellular vesicles
Microglial activation assessed by TNF-α concentration in culture supernatant after exposure to EVs isolated at baseline (0 hours) and 2 hours post intake. Cytokine concentration quantified using a validated immunoassay. Unit of Measure: pg/mL
Time frame: EVs isolated at baseline (0 hours) and 2 hours after beverage intake; cytokines assessed within 72 hours after EV isolation
IL1B mRNA expression in microglia after exposure to postprandial extracellular vesicles
Microglial activation assessed by IL1B mRNA expression after exposure to EVs isolated at baseline (0 hours) and 2 hours post intake. Gene expression quantified by RT-qPCR and reported as relative expression versus control condition. Unit of Measure: Fold change (dimensionless)
Time frame: EVs isolated at baseline (0 hours) and 2 hours after beverage intake; gene expression assessed within 72 hours after EV isolation
Endothelial VCAM-1 protein expression after exposure to postprandial extracellular vesicles
Endothelial activation assessed by VCAM-1 protein expression in cultured human umbilical vein endothelial cells after exposure to extracellular vesicles isolated from plasma at baseline (0 hours) and postprandial peak (2 hours). Protein expression quantified by immunoblotting or immunofluorescence and reported relative to control condition. Unit of Measure: Fold change (dimensionless)
Time frame: EVs isolated at baseline (0 hours) and 2 hours after beverage intake; assays conducted within 48 hours after EV isolation
Polyphenolic content of extracellular vesicles after wine intake
Identification and quantification of polyphenolic compounds encapsulated within plasma-derived extracellular vesicles following acute intake of red wine or white wine. Polyphenols will be analyzed using ultra-high-performance liquid chromatography coupled to quadrupole-Orbitrap mass spectrometry. Results will be expressed as normalized peak areas and concentrations relative to internal standards.
Time frame: Baseline (0 hours), postprandial peak (2 hours after beverage intake), and post-peak (6 hours after beverage intake).
Spearman correlation between EV cargo score and change from baseline in plasma glucose concentration
Association assessed using Spearman rank correlation (ρ) between EV cargo score (PC1 derived from normalized EV proteomic and lipidomic features measured by mass spectrometry) and the systemic response measure defined as change from baseline in plasma glucose concentration at postprandial time points. The outcome measure is Spearman's ρ. Unit of Measure: Spearman's ρ (dimensionless)
Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake (plasma glucose); EVs isolated at baseline (0 hours) and 2 hours after beverage intake
Endothelial ICAM-1 protein expression after exposure to postprandial extracellular vesicles
Endothelial activation assessed by ICAM-1 protein expression in cultured human umbilical vein endothelial cells after exposure to extracellular vesicles isolated from plasma at baseline (0 hours) and postprandial peak (2 hours). Protein expression quantified by immunoblotting or immunofluorescence and reported relative to control condition. Unit of Measure: Fold change (dimensionless)
Time frame: EVs isolated at baseline (0 hours) and 2 hours after beverage intake; assays conducted within 48 hours after EV isolation
Nitric oxide (NO) production in endothelial cell culture supernatant after exposure to postprandial extracellular vesicles
Endothelial response assessed by nitric oxide production after exposure to extracellular vesicles isolated from plasma at baseline (0 hours) and postprandial peak (2 hours). NO production quantified in culture supernatant using a validated colorimetric assay (e.g., nitrite/nitrate). Unit of Measure: µM
Time frame: EVs isolated at baseline (0 hours) and 2 hours after beverage intake; assays conducted within 48 hours after EV isolation
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Nov 2025 to primary completion in Dec 2025, 1 month.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 1 month is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.